Loading company
ONCBeone Medicines Ltd.$48BA+Built from Molecular Partners AG’s own filings with the U.S. Securities and Exchange Commission (SEC). Figures are as reported, with per-share history restated onto today’s share basis. This company files in CHF. Figures are converted to US dollars at $1.00 = 0.833140 CHF, the current rate, applied to every period alike — so growth and margins are the company’s own and not the exchange rate’s. This describes a business — it is not investment advice and not a recommendation to buy or sell anything.
The themes Molecular Partners is part of, the highest-graded companies in its industry, and the companies in its sector whose grade rose recently.
Graded A or B and worth $2B or more: A first, then the largest.
Rose to A or B on a filing in the last 90 days, worth $2B or more: largest first.
$3.220.0%Nov 6 close
Reported results on October 29, 2026; they are not in these figures yet.
Figures through December 31, 2025, from the 20-F filed March 12, 2026
Grade F
The band under the price shows the grade on each date, built only from filings that were public by then.
Showing 2 of 20 quarters of Molecular Partners AG’s grade history. The other 18 go back to March 2022.
